Emerging off-label uses for recombinant activated factor VII: Grading the evidence

T. Miko Enomoto, Per Thorborg

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.

Original languageEnglish (US)
Pages (from-to)611-632
Number of pages22
JournalCritical Care Clinics
Volume21
Issue number3 SPEC. ISS.
DOIs
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Emerging off-label uses for recombinant activated factor VII: Grading the evidence'. Together they form a unique fingerprint.

  • Cite this